Company intelligence / Profile preview

Okuvision

Reutlingen, Baden-Württemberg, Germanyokuvision.de ↗

Ownership: Private
Development stage: Commercial

Overview

Okuvision developed the transcorneal electrical stimulation therapy called OkuStim®, which has been CE marked. Clinical studies including multi-center post-market trials have shown that this therapy can delay progression of retinitis pigmentosa-related vision loss. Patients treated showed significant increases in their visual field after six weeks of treatment at certain stimulation levels. Ongoing studies aim to evaluate long-term benefits.

Therapeutic areas: Ophthalmology
Modalities: DeviceMedical technology for retinal disease treatment
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

OkuStim

Commercial

Indications: Retinitis pigmentosa, Choroideremia, Usher syndrome, Cone-rod dystrophy

Beyond the preview

Go deeper on Okuvision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Okuvision.

Explore the full profile